Derrick Ward, MD
Allergy & Immunology · Overland Park, KSNPI 1366490286
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.6% of the total across 331 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 18.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,648, 9.1 times the $181 reported in 2019.
Across 331 payments — averaging $17.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$1K
- AstraZeneca$823
- Regeneron Healthcare Solutions, Inc.$633
- GSK$436
- Takeda Pharmaceuticals U.S.A., Inc.$299
- Genentech USA, Inc.$286
- plus $2K from 30 others
Across 167 payments — averaging $17,171 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$1.9M
- Sanofi Pasteur Inc.$705K
- AstraZeneca$127K
- Currax Pharmaceuticals LLC$62K
- Teva Pharmaceuticals USA, Inc.$17K
- GSK$14K
- plus $21K from 2 others
What the payments were for
- Consulting fees$1052%
- Food & beverage$5,63896%
- Education$1523%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 75 | $1,068 |
| AstraZeneca | 44 | $823 |
| Regeneron Healthcare Solutions, Inc. | 42 | $633 |
| GSK | 23 | $436 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $299 |
| Genentech USA, Inc. | 16 | $286 |
| Grifols USA, LLC | 11 | $274 |
| Amgen | 12 | $230 |
| CSL Behring | 9 | $221 |
| Pharming Healthcare, Inc. | 8 | $153 |
| Sanofi-aventis U.S. LLC | 2 | $152 |
| Hospira, Inc. | 9 | $145 |
| Kaleo, Inc. | 6 | $138 |
| Biocryst US Sales Co., LLC | 7 | $121 |
| ADMA Biomanufacturing LLC | 6 | $105 |
| Optinose US, Inc. | 5 | $96 |
| Novartis | 6 | $90 |
| AbbVie | 3 | $74 |
| Lilly USA, LLC | 4 | $69 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $57 |
| Hikma Pharmaceuticals USA | 3 | $54 |
| Pfizer | 3 | $40 |
| Cycle Pharmaceuticals Inc | 2 | $34 |
| LEO Pharma Inc. | 2 | $33 |
| Octapharma USA, Inc. | 2 | $31 |
| Bio Products Laboratory USA, Inc. | 2 | $30 |
| Ionis Pharmaceuticals, Inc. | 1 | $29 |
| Boehringer Ingelheim | 1 | $24 |
| Greer Laboratories, Inc. | 1 | $22 |
| Seqirus USA Inc | 1 | $22 |
| Blueprint Medicines Corporation | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Arcutis Biotherapeutics, Inc. | 1 | $18 |
| Galderma Laboratories, L.p. | 1 | $17 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$243
How this compares
$5,895 in reported general payments places this provider in the 65th percentile of 33 allergy & immunology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 13 | $197,307 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 85 | $88,538 |
| Breo ElliptaFluticasone/Vilanterol | 56 | $34,907 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 21 | $16,260 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 86 | $13,642 |
| SymbicortBudesonide/Formoterol Fumarate | 34 | $13,574 |
| Advair HfaFluticasone Propion/Salmeterol | 14 | $8,818 |
| Arnuity ElliptaFluticasone Furoate | 18 | $6,239 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 33 | $5,705 |
| RyaltrisOlopatadine Hcl/Mometasone | 16 | $5,213 |
| Azelastine Hcl | 105 | $4,735 |
| Fluticasone-Salmeterol HfaFluticasone Propion/Salmeterol | 11 | $4,614 |
| Fluticasone Propionate | 104 | $2,539 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 22 | $2,353 |
| Montelukast Sodium | 192 | $2,094 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringHizentra | $221 | $197,30713 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $436 | $129,684159 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $823 | $29,83355 claims |
| Hikma Pharmaceuticals USARyaltris | $54 | $5,21316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 33 allergy & immunology providers in Kansas.
Other allergy & immunology in Overland Park
- Henry KanarekOverland Park$143K
- Celina BernabeOverland Park$95K
- William LaveryOverland Park$25K
- Sara AzzamOverland Park$19K
- Nguyen TranOverland Park$15K
- Cori PasserOverland Park$14K
- Mark NeustromOverland Park$3K
- James SternerOverland Park$3K
- H LevineOverland Park$3K
- Khaled GirgisOverland Park$636
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.